Must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or cutaneous disease amenable to serial measurements should be present; a measurable lesion is defined as a lesion that can be accurately measured in at least one dimension with the longest diameter >= 10 mm with computed tomography (CT) scan; lesions that have been treated with therapeutic intent will be considered measurable if they have increased in size by more than 20%
Participants must have measurable disease in the central nervous system (CNS), defined as at least one lesion that can be accurately measured in at least one dimension as >= 10 mm
Participants must have measurable disease in the CNS, defined as at least one lesion that can be accurately measured in at least one dimension as >= 5 mm (for cohorts A, B, D only)
Measurable disease by RECIST 1.1 (at least one lesion that can be accurately measured in at least one dimension > 20 mm with conventional imaging techniques or > 10 mm with spiral computed tomography [CT] or magnetic resonance imaging [MRI]) or evaluable disease; bone lesions (blastic, lytic, or mixed) in the absence of measurable disease as defined above are also acceptable
At least one lesion, not previously irradiated, that can be accurately measured at baseline as >= 10 mm in the longest diameter (except lymph nodes which must have short axis >= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or >= 10 mm with calipers by clinical exam OR at least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray/clinical exam at baseline and follow up visits
All patients must have measurable disease; measurable disease is defined as lesions which can be measured by physical examination or by means of medical imaging techniques; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be >= 20 mm when measured by conventional techniques, including palpation or plain x-ray, or >= 10 mm when measured by spiral computed tomography (CT) and/or magnetic resonance imaging (MRI); ascites and pleural effusions are not to be considered measurable disease
Patients must have measurable disease or non-measurable (detectable) disease:\r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI\r\n* Non-measurable (detectable) disease in a patient is defined in this protocol as one who does not have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria but does have a cancer antigen 125 (CA-125) greater than or equal to two times the upper normal limit within the last 60 days (confirmatory at baseline) and at least one of the following conditions:\r\n** Ascites and/or pleural effusion attributed to tumor\r\n** Hypermetabolic lesions on positron emission tomography (PET) scan
Patients must have measurable disease or detectable (non-measurable) disease: \r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI; tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy\r\n* Detectable disease in a patient is defined as one who does not have measurable disease but has at least one of the following conditions in the setting of a CA125 > 2 x upper limit of normal (ULN):\r\n** Ascites and/or pleural effusion attributed to tumor\r\n** Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v.1.1.
Patients must have radiographically measurable disease (with the exception of neuroblastoma), Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm).
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least two dimensions on magnetic resonance imaging (MRI)
All patients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension
STUDY ENTRY: All patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray. Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in Response Evaluation Criteria in Solid Tumors (RECIS)T version 1.1
All patients must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be ? 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or ? 20 mm when measured by chest x-ray; lymph nodes must be ? 15 mm in short axis when measured by CT or MRI
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v)1.1\r\n* NOTE: Scans must be =< 28 days prior to study treatment
Have measurable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. For the purposes of this study measurable disease is defined at least one \target\ lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each target lesion must be > 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or > 10 mm when measured by spiral CT. The target lesion must be distinct from other tumor areas selected for pre-treatment biopsies. Pre-treatment imaging must be performed within 4 weeks of starting therapy.
All patients must have measurable disease that can be assessed using RECIST 1.1 criteria, which is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or CT scan that can be accurately measured with the longest diameter of 10 mm in at least one dimension; for this phase II trial, patients with disease limited to bone or marrow metastases are NOT eligible
Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded). Each lesion must be greater than or equal to (>=) 10 millimeter (mm) in long axis when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam. Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension
Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 OR non-measurable tumors; NOTE: Non-measurable tumors are small lesions (longest diameter < 10 mm or pathological lymph nodes with >= 10 to < 15 mm short axis); bone lesions, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by computed tomography [CT] or magnetic resonance imaging [MRI]) are considered as non-measurable
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 \r\n* Measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each target lesion must be > 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or > 10 mm when measured by spiral CT\r\n* Patients with non-measurable but evaluable solid tumors may be deemed eligible contingent upon principal investigator (PI) review; a non-measurable but evaluable solid tumor is defined as either unidimensionally measurable lesions, masses with margins not clearly defined, or lesions with maximal perpendicular diameters < 10 mm that can still be evaluated for the primary endpoint
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (at least one lesion >= 10mm in at least one dimension when assessed by computed tomography [CT] or magnetic resonance imaging [MRI], or a cutaneous lesion with clearly defined margins that measures >= 10 mm in at least one dimension)
PHASE I:\r\n* Patients must have recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma for which standard curative measures do not exist and be confirmed to carry a germline mutation in the BRCA1 or BRCA2 gene\r\n* All patients must have measurable disease as defined by World Health Organization (WHO) criteria; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be > 1.0cm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or > 2.0 cm when measured by chest x-ray; lymph nodes must be > 1.5 cm in short axis when measured by CT or MRI\r\n* Patients with both platinum-sensitive and platinum-resistant disease are eligible
PHASE II:\r\n* Patients must have recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and be confirmed to carry a germline mutation in BRCA1 or BRCA2\r\n* All patients must have measurable disease as defined by WHO criteria; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be > 1.0 cm when measured by CT, MRI, or caliper measurement by clinical exam; or > 2.0 cm when measured by chest x-ray; lymph nodes must be > 1.5 cm in short axis when measured by CT or MRI\r\n* Patients with both platinum-sensitive and platinum-resistant disease are eligible
The patient must have a stable clinical (neurologic in case of brain tumors) exam and be on a stable dose of steroids for at least 1 week prior to study entry; the patient should have a measurable and/or evaluable disease; measurable disease which is defined as the presence of at least one lesion that can be accurately measured in two dimensions (each measures at least 10 mm) or evaluable disease which is defined as at least one lesion that can be accurately measured in at least one dimension (measure at least 10 mm)
Patients must have measurable disease and is defined as a lesion that can be accurately measured on the long axis with a minimum size of 10 mm or a lymph node that can be accurately measured along the short axis of a minimum size of 15 mm (computed tomography [CT] scan slice thickness can be no greater than 5 mm)
Measurable disease is required; by definition, measurable disease is at least one lesion that can be accurately measured in at least on dimension with the longest dimension to be recorded; each lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), magnetic resonance imaging (MRI) or >= 10 mm when measured by spiral CT imaging
Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension; at least one biopsiable lesion must be available; when imaging (DCE-MRI, DW-MRI and PET-computed tomography [CT] imaging) is being performed for secondary objectives (dose level III [or when the dose reaches at least 1,500 ug/m^2] and during the expansion phase) at least one lesion (>= 2 cm) not adjacent to the diaphragm will be required when measured by conventional techniques, including palpation, plain x-ray, CT, and MRI; a second lesion accessible for biopsy must also be present; patients must have at least one 'target lesion' to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST); this may be one of the lesions mentioned above; tumors within a previously irradiated field will be designated as 'non-target' lesions
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm by computed tomography (CT) scan, positron emission tomography (PET)/CT scan, magnetic resonance imaging (MRI) or caliper/ruler measurement by clinical exam; lymph nodes: to be considered pathologically enlarged and measurable, a lymph node must be >= 15 mm in short axis when assessed by CT scan; lesions that have been radiated in the advanced setting cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI
Patients must have measurable disease by RECIST v1.1. a. Measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each target lesion must be > 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or > 10 mm when measured by spiral CT.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined at least two lesions that can be accurately measured in at least one dimension (longest dimension to be recorded); each \target\ lesion must be > 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or > 10 mm when measured by spiral CT; positron emission tomography (PET)/CT will be acceptable at baseline if PET/CT was previously performed and available; imaging must be within 4 weeks of starting therapy; the target lesion must be distinct from other tumor areas selected for pre-treatment biopsies
For subject with extracranial disease, they must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as >= 10 mm in the longest diameter (except lymph nodes which must have short axis >= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or >= 10 mm with calipers by clinical exam OR at least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/pain x-ray/clinical exam at baseline and follow up visits
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT, PET/CT, or MRI\r\n* Detectable disease in a patients is defined as one who does not have measurable disease, but has at least one of the following conditions:\r\n** Baseline values of CA-125 at least 2 x upper limit of normal (ULN)\r\n** Ascites and/ or pleural effusion attributed to tumor\r\n** Solid and/ or cystic abnormalities on radiographic imaging that do not meet modified RECIST criteria, immune-related response criteria (irRC) for target lesions
All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have measurable disease, defined by RECIST version (v) 1.1 as at least one lesion that can be accurately measured in at least one dimension of >= 10 mm by computed tomography (CT), magnetic resonance imaging (MRI), or calipers
All patients must have measurable disease; measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography [CT], magnetic resonance imaging [MRI] or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease; measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1), with radiologic scans performed within 30 days of registration; baseline scans can include:\r\n* CT scan or magnetic resonance imaging (MRI) and bone scan OR\r\n* Positron emission tomography (PET)/CT provided the PET/CT is performed with both intravenous (IV) and oral contrast and the CT is acquired with 5 mm or less slice thickness; if IV contrast administration is contraindicated, patients should have CT scan without contrast and bone scan or MRI and bone scan\r\n* MRI of the brain will be used for baseline assessment and tumor response assessment for CNS lesions\r\n* Patients with CNS progression without systemic progression will be allowed to remain on the protocol; local treatment, radiation, surgery, and stereotactic radiosurgery (SRS) will be allowed while on protocol as deemed necessary by the treating physician\r\n* The baseline imaging method(s) should be used to determine tumor response throughout the course of the study\r\n* Measurable disease: lesions with clearly defined margins that can be accurately measured in at least one diameter (longest diameter to be recorded) with a minimum size of :\r\n** 10 mm by CT scan (CT scan slice thickness no greater than 5 mm)\r\n** 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable)\r\n** 20 mm by chest x-ray\r\n** Malignant lymph nodes: to be considered pathologically enlarged and measurable, a lymph node must be >= 15 mm in short axis when assessed by CT scan; at baseline and in follow-up, only the short axis will be measured and followed\r\n* Non-measurable disease: all other lesions, including small lesions (longest diameter: all other lesions, including small lesions (longest diameter < 10 mm or pathological lymph nodes with >= to < 15 mm [short axis]), and masses with margins not clearly defined; lesions that are considered non-measurable include:\r\n** Bone lesions\r\n** Leptomeningeal disease\r\n** Ascites\r\n** Pleural/pericardial effusion\r\n** Inflammatory breast disease\r\n** Abdominal masses that are not confirmed and followed by imaging techniques\r\n** Cystic lesion\r\n** Lymphangitic involvement of skin or lung
All patients diagnosed with recurrence must have measurable disease; in recurrent patients, paraffin embedded USPC tumor tissue must be available from either primary surgery, tumor purified from ascites or from computed tomography (CT)-guided biopsy of recurrent disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be >= 20 mm when measured by conventional techniques, including palpation or plain x-ray, or >= 10 mm when measured by spiral CT and/or magnetic resonance imaging (MRI)
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20 mm when measured by conventional techniques, MRI or CT, or more than or equal to 10 mm when measured by spiral CT
Patients must have measurable disease or detectable (non-measurable) disease:\r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI\r\n* Detectable disease in a patient is defined as one who does not have measurable disease but has baseline value of cancer antigen (CA)-125 at least 2 x upper limit of normal (ULN)
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI; all imaging studies must be performed within 28 days prior to registration
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Measurable disease (Response Evaluation Criteria In Solid Tumors [RECIST]): defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20mm when measured by conventional techniques, magnetic resonance imaging (MRI) or computed tomography (CT), or more than or equal to 10 mm when measured by spiral CT
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria version (v.) 1.1
Patients must have disease that is measurable according to RECIST 1.1 or assessable according to the GCIG CA-125 criteria and require chemotherapy treatment; part 1: patients must have one or more measurable target lesion; part 2: patients must have two or more measurable target lesions; measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each 'target' lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by spiral CT
All patients must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease. Measurable disease is defined by RECIST version 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be greater than or equal to 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray. Lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI (See section 8).
at least 1 superficial cutaneous or subcutaneous melanoma lesion that can be accurately and serially measured in at least 2 dimensions and for which the short axis is ? 5 mm as measured by calipers
Must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.
All patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 defined as at least one \target lesion\ that can be accurately measured in at least one dimension (>= 10 mm longest dimension to be recorded; Lymph nodes must be >= 15 mm per short axis). Each lesion must be > 20 mm when measured by palpation or conventional imaging techniques (computed tomography [CT] or magnetic resonance imaging [MRI] - based on primary physician preference) or >10 mm with spiral CT scan. Measurable lesions must be at least 2 times the slice thickness in millimeters. Tumors within a previously irradiated field will be designated as \non-target\ lesions unless progression is documented. Ascites and pleural effusions are not considered measurable disease. If the measurable disease is confined to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.
Patients must have measurable disease; measurable disease is defined by RECIST (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and has not been previously irradiated; each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Have measurable disease or detectable (non-measureable) disease:\r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI\r\n* Detectable (non-measurable) disease is defined as not having measurable disease but has:\r\n** Baseline values of CA-125 at least 2 x upper limit of normal (ULN); AND EITHER\r\n*** Ascites and/or pleural effusion attributed to tumor; OR\r\n*** Solid and/or cystic abnormalities on radiographic imaging consistent with recurrent disease that do not meet RECIST 1.1 definitions for target lesions
Patients must have measurable disease (RECIST 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by spiral computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm with conventional techniques; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Participants must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm by local radiology review (note: measurable non-CNS disease is NOT required for study participation)
All patients must have measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined as at least one target lesion that can be accurately measured in at least one dimension (>= 10 mm longest dimension to be recorded; lymph nodes must be >= 15 mm per short axis); each lesion must be > 20 mm when measured by palpation or conventional imaging techniques (computed tomography [CT] or magnetic resonance imaging [MRI]-based on primary physician preference) or > 10 mm with spiral CT scan; measurable lesions must be at least 2 times the slice thickness in millimeters; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented; ascites and pleural effusions are not considered measurable disease; if the measurable disease is confined to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. or cutaneous disease amenable to serial measurements should be present; measurable disease (a 'target' lesion) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT) (CT scan slice thickness no greater than 5 mm); >= 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable); and >= 20 mm by chest x-ray
Patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with longest dimension >= 10 mm by local radiology review; Note: measurable non-CNS disease is NOT required for study participation
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded)\r\n* Each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray\r\n* Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease; measurable disease is defined by RECIST (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease that is amenable to biopsy; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be >= 20 mm when measured by conventional techniques including palpation, plain film x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by high resolution CT
All patients must have measurable disease at screening by RECIST 1.1 criteria; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter (LD) >= 10 mm using computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurements or >= 20 mm with x-ray
All patients must have measurable cervical cancer or vaginal cancer disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 40 mm when measured preferably by clinical exam or alternatively by computed tomography (CT), magnetic resonance imaging (MRI)
Measurable disease (at least one measurable lesion) IS required; a measurable lesion is one that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be > 10 mm when measured by computed tomography (CT) scan, magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or > 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI
Patients must have measurable disease; measurable disease is defined by RECIST (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients with histologically or cytologically confirmed, epithelial ovarian, primary peritoneal or fallopian tube cancer who experienced recurrence or progression within 12 months after completion of platinum based chemotherapy; patients must have measurable disease or detectable disease: \r\n* Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be greater than or equal to 10 mm when measured by computerized tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT, PET/CT or MRI\r\n* Detectable disease in a patient is defined as one who does not have measurable disease, but has at least one of the following conditions: \r\n** Baseline values of cancer antigen-125 (CA-125) at least 2 x upper limit of normal (ULN) \r\n** Ascites and/or pleural effusion attributed to tumor \r\n** Solid and/or cystic abnormalities on radiographic imaging that do not meet modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria, immune-related response criteria (irRC) for target lesions
Participants must have measurable disease defined as at least one target lesion that has not been irradiated and can be accurately measured in at least one dimension by RECIST v1.1 criteria.
At least 1 measurable Target Lesion that can be accurately measured by calipers or computed tomography (CT) consisting of:
Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST 1.1
Measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension; each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Measurable disease criteria as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured by CT or MRI
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. \r\n* Measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each “target” lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by spiral CT\r\n* Patients with non-measurable but evaluable solid tumors may be deemed eligible contingent upon principal investigator (PI) review
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by RECIST criteria version (v)1.1
Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as >= 10 mm with MRI, performed within 30 days prior to study registration